Studies on a new beta-receptor blocking drug, tobanum--1-(2,5-dichlorophenoxy)-3-tertiary-butylamino-2-propanol HCl: its use in cardiovascular hyperkinetic syndrome, hypertension, and angina pectoris, and its effect on respiration.
The effect of the beta-receptor blocking drug Tobanum was examined in 10 patients with idiopathic hyperkinetic heart syndrome. The circulation (arm-to-ear) time was determined by indicator-dilution method following methylene blue injection. The appearance, concentration, and dilution time was prolonged in each case 120 min after a single dose of 2.5 mg Tobanum. The heart rate decreased significantly. The hypotensive effect of Tobanum has been evaluated in 10 patients. A 2-week "wash-out" period preceded 5 weeks of adaptive dose administration (7.5-45 mg), and 2 weeks of placebo concluded the study. Both systolic and diastolic pressure and heart rate decreased during treatment with the drug. However, a significant increase again thereafter was observed in both standing and lying positions. The number of anginal attacks, amount of nitroglycerin consumption and the "angina index" decreased significantly in 5 of 10 patients with stable angina during the active treatment period (3 X 2.5 mg daily). Only in 1 case of 10 bronchitis patients and 10 healthy persons was a deterioration of vital capacity and FEV1 values found after a single dose of 2.5 mg Tobanum.